# 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

> **NCT02477800** · PHASE3 · TERMINATED · sponsor: **Biogen** · enrollment: 1653 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Aducanumab (BIIB037)
- **DRUG:** Aducanumab (BIIB037)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02477800
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08-13
- **Primary completion:** 2019-08-08
- **Final completion:** 2019-08-08
- **Target enrollment:** 1653 (ACTUAL)
- **Why stopped:** Study was discontinued based on futility analysis done and not based on safety concerns. Follow-up visits and closing out study activities are completed
- **Last updated:** 2021-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02477800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02477800, "221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02477800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*